Tirzepatide benefits people with obesity, kidney disease and heart failure
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...
Medindia1d
Tirzepatide: Combating Obesity, Kidney Disease, and Heart Failure Together
Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...
Medscape1d
Obesity ‘Strongly’ Linked to 16 Cardiometabolic Diseases
The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...
Ozempic for heart disease? Doctors think it’s worth considering
The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...
Social factors help explain worse cardiovascular health among adults in rural vs. urban communities
A research team has uncovered higher rates of heart disease and worse heart health affecting adults living in rural ...
Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity
A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...
University of South Florida10d
USF student gets to the heart of obesity
In the United States, obesity is estimated to cause between 280,000 and 374,000 deaths each year and more than $170 billion ...
Eating Slower Can Significantly Reduce Obesity Risk
Obesity remains a global health crisis, often linked to serious diseases such as diabetes, heart disease, and fatty liver ...
Sierra Sun Times2d
NIH Reports Social Factors Help Explain Worse Cardiovascular Health Among Adults in Rural vs. Urban Communities
NIH Reports Social Factors Help Explain Worse Cardiovascular Health Among Adults in Rural vs. Urban Communities ...